Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -10.79%
H: 0.0%
C: -3.75%
gtx-102 positive treatment
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Euro Tech Holdings Company Limited Reported An Exclusive Sales Distribution And OEM Partnership Agreement Covering Ballast Water Treatment Systems ("BWTS") Has Been Signed Between PACT And ERMA FIRST
Published: 2024-04-15 (Crawled : 11:00) - prnewswire.com
CLWT | $1.54 0.0% 1.5K
|
Electronic Technology
|
| O: 1.1%
H: 0.19%
C: 0.19%
sales water partnership first company distribution treatment agreement
A New Generation of Antidepressant Drug Precision Treatment Based on Revolutionary AI Technology is Born
Published: 2024-04-15 (Crawled : 10:00) - prnewswire.com
NCTY | $6.11 1.83% 1.8% 19K
|
Technology Services
|
| O: -4.94%
H: 0.0%
C: 0.0%
drug precision treatment technology
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta abbvie treatment for migraine
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Published: 2024-04-11 (Crawled : 14:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -1.08%
H: 1.63%
C: -2.72%
first solution light treatment for study
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS’ SUMMIT
Published: 2024-04-11 (Crawled : 12:00) - apyxmedical.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
APYX | $1.325 -3.99% -4.15% 57K
|
Health Technology
|
| O: 2.8%
H: 5.44%
C: 5.44%
renuvion corporation treatment medical apyx
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.47%
H: 1.16%
C: -1.27%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.34%
H: 0.27%
C: -0.62%
children approved treatment for
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: 0.72%
H: 1.6%
C: -0.36%
metabolic treatment for
Soil Treatment Market size is set to grow by USD 16.46 billion from 2023-2027, Need to meet rising demand for crops boost the market, Technavio
Published: 2024-04-10 (Crawled : 13:30) - prnewswire.com
CODYY | $15.06 -0.13% 99K
|
Manufacturing
|
| O: -3.01%
H: 1.44%
C: 0.84%
treatment for set market
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: -3.03%
H: 7.03%
C: -0.78%
patent disorders treatment for application
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Published: 2024-04-10 (Crawled : 11:00) - biospace.com/
TBPH | $9.35 1.63% 1.6% 430K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.